Key clinical point: Combination pembrolizumab, bevacizumab, and oral metronomic cyclophosphamide demonstrated efficacy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Major finding: The tumor response rate with the three-drug regimen (40%) was better than response rates previously reported for pembrolizumab monotherapy and bevacizumab plus cyclophosphamide.
Study details: A phase 2 trial of 40 patients.
Disclosures: The trial was sponsored by Roswell Park Cancer Institute in collaboration with the National Cancer Institute. The speaker reported relationships with Iovance Biotherapeutics and AstraZeneca
Zsiros E et al. SGO 2019, Abstract LBA4.